Recent News

• 09.03.2025 - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
• 09.03.2025 - Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program
• 08.07.2025 - Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
• 08.07.2025 - Rallybio Reports Second Quarter 2025 Financial Results and Provides Business Updates
• 07.08.2025 - Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
• 07.08.2025 - Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals
• 06.12.2025 - Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study
• 06.12.2025 - Rallybio Initiates Dosing in RLYB116 Phase 1 Confirmatory Pharmacokinetic/Pharmacodynamic Study

Recent Filings

• 08.29.2025 - 8-K Current report
• 08.07.2025 - EX-99.1 EX-99.1
• 08.07.2025 - 8-K Current report
• 08.07.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 07.08.2025 - 8-K Current report
• 07.08.2025 - EX-99.1 EX-99.1
• 06.27.2025 - 8-K Current report
• 05.16.2025 - 8-K Current report
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.15.2025 - 4 Statement of changes in beneficial ownership of securities